ReviewMediators of inflammation2014
The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis.
Review in Mediators of inflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 2 syntheses or guidelines pooled it, 164 citations in OpenAlex.
- Variable roles of interleukin-17F in different cancers.BMC cancer · 2022Pooled it
- Rs-10889677 variant in interleukin-23 receptor may contribute to creating an inflammatory milieu more susceptible to bladder tumourigenesis: report and meta-analysis.Immunogenetics · 2021Pooled it
- Inflammation and RNA-Related Polymorphisms in Resected Cholangiocarcinoma: Prognostic Associations in Intrahepatic and Perihilar Tumors.Journal of gastrointestinal cancer · 2026Article
- Exploring the Vasculitis-Tumors Link: Epidemiological Patterns, Mechanistic Insights, and Clinical Implications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Strategies for Optimal Use of Biological Therapies in Managing Psoriasis: Focus on Secukinumab.Dermatology and therapy · 2025Article
- Co-Targeting PD-1 and IL-33/ST2 Pathways for Enhanced Acquired Anti-Tumor Immunity in Breast Cancer.International journal of molecular sciences · 2025Article
- The impact of serum interleukin-17a as a predictive biomarker for neoadjuvant therapy response in breast cancer: a retrospective study.Gland surgery · 2025Article
- Review
- Article
- Immunomodulatory Effects ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Review
- Article
- Potential Pathogens Associated with Colorectal Cancer.Current pharmaceutical biotechnology · 2025Review
- Hypercholesterolemia and the role of lipid metabolism gene CES1 in immune infiltration promote central nervous system relapse in acute myeloid leukemia.Frontiers in immunology · 2025Article
- Interleukins as a potential link between obstructive sleep apnea and renal cell carcinoma.Contemporary oncology (Poznan, Poland) · 2025Review
- The Intersection of Psoriasis and Neoplasia: Risk Factors, Therapeutic Approaches, and Management Strategies.Cancers · 2024Review
- NF-κB role on tumor proliferation, migration, invasion and immune escape.Cancer gene therapy · 2024Review
- Potential Aspects of the Use of Cytokines in Atopic Dermatitis.Biomedicines · 2024Review
- Review
- Innate immune cells: Key players of orchestra in modulating tumor microenvironment (TME).Heliyon · 2024Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With 7.6 million deaths globally, cancer according to the World Health Organisation is still one of the leading causes of death worldwide. Interleukin 17 (IL-17) is a cytokine produced by Th17 cells, a T helper cell subset developed from an activated CD4+ T-cell. Whilst the importance of IL-17 in human autoimmune disease, inflammation, and pathogen defence reactions has already been established, its potential role in cancer progression still needs to be updated. Interestingly studies have demonstrated that IL-17 plays an intricate role in the pathophysiology of cancer, from tumorigenesis, proliferation, angiogenesis, and metastasis, to adapting the tumour in its ability to confer upon itself both immune, and chemotherapy resistance. This review will look into IL-17 and summarise the current information and data on its role in the pathophysiology of cancer as well as its potential application in the overall management of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.